Pivanex problems in Phase IIb
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Titan discontinues the Pivanex plus docetaxel arm of its Phase IIb non-small cell lung cancer study after an interim analysis identifies "significant safety issues" with combination treatment. Prior single-agent Phase I and Phase II studies and a dose-ranging study of the combo did not reveal toxicity issues, the firm says. Other arms in the NSCLC study will continue, but Titan will withhold further treatment and enrollment in open-label Phase IIa studies in chronic lymphocytic leukemia and melanoma "until further analysis of the data from the Phase IIb study is available." Pivanex inhibits histone deacetylases, a class of enzymes involved in cell growth...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.